

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of Financial status**  
**as of 31 of December 2021**

	<b>31.12.2021</b>	<b>31.12.2020</b>
	<i>BGN'000</i>	<i>BGN'000</i>
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	36 848	37 123
Intangible assets	3 481	3 816
Assets with usable assets	19	210
Trade receivables	5 157	5 176
<b>Total non-current assets</b>	<b>45 505</b>	<b>46 325</b>
<b>Current assets</b>		
Inventories	10 773	10 842
Trade and other receivables	60 184	60 084
Current corporate income tax	-	14
Treasury shares redeemed	-	1
Cash and cash equivalents	40	45
<b>Total current assets</b>	<b>72 044</b>	<b>70 986</b>
<b>Total assets</b>	<b>116 502</b>	<b>117 311</b>
<b>LIABILITIES</b>		
<b>Equity</b>		
Share capital	84 500	82 200
Reserves	12 094	12 032
Retained earnings	2 209	2 904
<b>Total</b>	<b>98 803</b>	<b>97 136</b>
<b>Non-current liabilities</b>		
Long-term loans	1 769	1 731
Deferred tax liabilities	1 139	1 139
Retirement benefit obligations	194	194
<b>Total non-current liabilities</b>	<b>3 102</b>	<b>3 064</b>
<b>Current liabilities</b>		
Trade and other liabilities	4 350	6 583
Short-term loans	9 781	9 783
Current portion of long-term loans	342	541
Current corporate income tax		
Other tax liabilities	124	204
<b>Total current liabilities</b>	<b>14 597</b>	<b>17 111</b>
<b>Total liabilities</b>	<b>17 699</b>	<b>20 175</b>
<b>Total equity and liabilities</b>	<b>116 502</b>	<b>117 311</b>

Date of preparation: 25.01.2022

Sofia

Prepared by:.....  
 / P. Moneva /

Executive Director:.....  
 / B. Georgiev /

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of comprehensive income**  
**as of 31 of December 2021**


	<b>31.12.2021</b>	<b>31.12.2020</b>
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	42 431	40 105
Other income	101	283
<b>Total income</b>	<b>42 532</b>	<b>40 388</b>
Carrying amount of goods sold	(1 105)	(817)
Changes in inventories of finished products and work in progress	1 021	(784)
Materials and services	(30 657)	(28 405)
Personnel expenses	(5 441)	(4 960)
Depreciation / amortisation expenses	(3 795)	(4 231)
Other expenses	(759)	(652)
Finance income	501	521
Finance costs	(389)	(436)
<b>Total expenses</b>	<b>(40 633)</b>	<b>(39 764)</b>
<b>Profit before taxation</b>	<b>1 899</b>	<b>624</b>
Corporate income tax expense	(232)	(196)
<b>Profit/Loss for the period</b>	<b>1 667</b>	<b>428</b>
<b>Other comprehensive income for the period</b>		<b>165</b>
<b>Total comprehensive income for the period</b>	<b>1 667</b>	<b>593</b>
Earnings per share / in BGN per 1 share /	0.02	0.007

Date of preparation: 25.01.2022

Sofia

Prepared by:.....  
 / P. Moneva /

Executive Director:.....  
 /B. Georgiev/



**Tchaikapharma High Quality Medicines Inc.**  
**Interim cash flow statement**  
**as of 31 of December 2021**

	<b>31.12.2021</b>	<b>31.12.2020</b>
	<i>BGN'000</i>	<i>BGN'000</i>
<b>Cash flows from operating activities</b>		
Proceeds from sale of finished products, goods and services	33 931	35 208
Payments to suppliers of materials, goods and services	(22 956)	(22 940)
Payments to personnel	(5 113)	(4 802)
Payments of interest and dividends	(218)	(352)
Other proceeds / payments	(3 369)	(3 628)
<b>Net cash flows</b>	<b>2 275</b>	<b>3 486</b>
<b>Cash flows from investing activities</b>		
Payments on non-current assets acquired	(1 573)	(2 907)
Other post/payments for investment activity		(19)
<b>Net cash flows</b>	<b>(1 573)</b>	<b>(2 655)</b>
<b>Cash flows from financial activities</b>		
Proceeds from loans	199	200
Payments on loans	(200)	(201)
Payment of interest, dividends	(247)	(196)
Payments on finance lease	(459)	(358)
<b>Net cash flows</b>	<b>(707)</b>	<b>(555)</b>
<b>Change in cash and cash equivalents</b>	<b>(5)</b>	<b>5</b>
Cash and cash equivalents at the beginning of the period	45	40
<b>Cash and cash equivalents at the end of the period</b>	<b>40</b>	<b>45</b>

Date of preparation: 25.01.2022

Sofia

Prepared by:.....

/P. Moneva /

Executive  
Director:.....

/B. Georgiev /

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement on changes in equity**  
**as of 31 of December 2021**

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
<b>Balance as of 01.01.2020</b>	<b>82 200</b>	<b>4 099</b>	<b>7 676</b>	<b>2 568</b>	<b>96 543</b>
Profit/loss for the period				604	604
Other comprehensive income		(11)			(11)
Including from tax effect of the revaluation of property, plant and equipment					
<b>Total comprehensive income</b>		<b>(11)</b>		<b>604</b>	<b>593</b>
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			268	(268)	
<b>Total amount of income and expenses recognised during the period</b>			<b>268</b>	<b>(268)</b>	
<b>Balance as of 31.12.2020</b>	<b>82 200</b>	<b>4 088</b>	<b>7 944</b>	<b>2 904</b>	<b>97 136</b>
<b>Balance as of 01.01.2021</b>	<b>82 200</b>	<b>4 088</b>	<b>7 944</b>	<b>2 904</b>	<b>97 136</b>
Profit/loss for the period				1 667	1 667
Other comprehensive income					
<b>Total comprehensive income</b>				<b>1 667</b>	<b>1 667</b>
Issue of shares by the owners	2 300			(2 300)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			62	(62)	
<b>Total amount of income and expenses recognised during the period</b>	<b>2 300</b>		<b>62</b>	<b>(2 362)</b>	
<b>Balance as of 31.12.2021</b>	<b>84 500</b>	<b>4 088</b>	<b>8 006</b>	<b>2 209</b>	<b>98 803</b>

Date of preparation: 25.01.2022  
Sofia

Prepared by:.....

/P. Moneva/

Executive Director.....

/B. Georgiev /